18 October 2017
|Location:||Large Lecture Theatre University of Westminster, Cavendish Campus, 115 New Cavendish Street, London, W1W 6XH – View map|
Epilepsy is a devastating neurological condition that has affected humanity from time immemorial. Treatment throughout this time has been wide-ranging in nature, with varied level of success. More recently there has been a resurgence in the interest in the use of cannabis in the treatment of epilepsy. A number of clinical trials, with cannabis derived compounds such as Cannabidiol (CBD) having significant therapeutic benefits in neurologic conditions such as epilepsy. However, there still is a significant research paucity in our understanding of the use of medical cannabis in epilepsy.
In this Public Lecture, Professor Geoffrey Guy will give a historical overview of the use of cannabis and cannabis derived products in the treatment of epilepsy and will present and discuss the latest research in this sometime contentious, yet rapidly expanding, area of social, scientific and medical importance.
Professor Geoffrey Guy is the founder and owner of GW Pharma, a highly successful biotech company and one of the world leaders in the development and commercialisation of herb-derived medicines, including cannabinoids. Professor Guy is also an outstanding scientist who has worked closely with leading scientific institutions, including the University of Westminster, in determining the mode-of-action of some of these natural compounds and their effects on health and disease. He has published widely, with many highly cited papers and reviews in the area of cannabinoids and mitochondrial function.
Professor Guy is in the unique position of having successfully brought to market medicines derived from plants; an experience that is invaluable to the search for new medicines. Moreover, his in-depth knowledge of the biotech market and medical community is highly relevant to many sectors of society including Medicine, Business and the Social Sciences.
Tickets are available on a first come first served basis. Register now.